Bionano Genomics, Inc.
BNGO
$3.65
-$0.05-1.35%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -24.04% | -14.79% | -0.82% | 16.08% | 26.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -24.04% | -14.79% | -0.82% | 16.08% | 26.93% |
| Cost of Revenue | 3.02% | 14.48% | 37.50% | 10.47% | 21.39% |
| Gross Profit | -95.21% | -96.03% | -106.71% | 32.58% | 44.22% |
| SG&A Expenses | -65.84% | -56.64% | -40.59% | -22.38% | -1.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -54.47% | -45.17% | -30.21% | -18.45% | 0.65% |
| Operating Income | 63.24% | 52.98% | 36.89% | 26.00% | 5.02% |
| Income Before Tax | 63.12% | 51.82% | 39.75% | -41.11% | -64.49% |
| Income Tax Expenses | 222.22% | -46.77% | -100.21% | -99.42% | -99.05% |
| Earnings from Continuing Operations | 63.10% | 51.82% | 40.26% | -39.30% | -62.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 63.10% | 51.82% | 40.26% | -39.30% | -62.26% |
| EBIT | 63.24% | 52.98% | 36.89% | 26.00% | 5.02% |
| EBITDA | 70.51% | 58.96% | 42.16% | 29.49% | 7.72% |
| EPS Basic | 84.09% | 77.08% | 64.87% | -5.94% | -29.31% |
| Normalized Basic EPS | 84.14% | 75.86% | 51.41% | 36.62% | 14.37% |
| EPS Diluted | 84.09% | 77.08% | 64.87% | -5.92% | -29.28% |
| Normalized Diluted EPS | 84.14% | 75.86% | 51.41% | 36.62% | 14.37% |
| Average Basic Shares Outstanding | 160.20% | 123.39% | 94.63% | 62.13% | 35.47% |
| Average Diluted Shares Outstanding | 160.20% | 123.39% | 94.63% | 62.13% | 35.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |